BRB 002
Alternative Names: BRB-002Latest Information Update: 03 May 2024
At a glance
- Originator Bitterroot Bio
- Class Anti-inflammatories; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action CD47 antigen inhibitors; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atherosclerosis
- Preclinical Vasculitis